HOME >> BIOLOGY >> NEWS
Rockefeller University Researchers Hunt For Type 2 Diabetes Susceptibility Genes

The Rockefeller University is looking for people with type 2 diabetes to participate in a study aimed at determining the genetic causes of early- and late-onset forms of the disease. The study is part of the research program of the university's Starr Center for Human Genetics.

"We hope that by identifying genes that cause type 2 diabetes we can develop better diagnostic tools and improved drug therapies, and in the long term, a possible way of preventing this disease," says Assistant Professor Markus Stoffel, M.D., Ph.D., principal investigator of the study and head of the Laboratory of Metabolic Diseases. Stoffel, the university's Robert and Harriet Heilbrunn Professor, is an Irma Hirschl Scholar and a Pew Scholar. He received the Career Development Award in 1997 from the American Diabetes Association.

Genes constitute some of the most important risk factors for type 2 diabetes, although environment also plays a role in the disease. Most common forms of diabetes are polygenic, meaning that more than one gene is involved in the disease, making it difficult to identify the genes responsible. By enrolling a large number of participants, the study investigators hope to identify as many type 2 diabetes susceptibility genes as possible.

Type 2 diabetes is caused by ineffective insulin secretion or improper insulin action on target tissues such as muscle, leading to impaired glucose uptake from the blood and increased levels of blood glucose. Type 2 diabetes is the most common form of diabetes, accounting for 90 to 95 percent of cases. In about 5 percent of cases, inheritance follows a classic autosomal dominant pattern?anyone in a family who has one copy of the defective gene is likely to develop hyperglycemia or increased levels of blood glucose?and is characterized by an early age of onset.. Known as maturity onset-diabetes of the young (MODY), this form of diabetes usually develops before age 25. S
'"/>

Contact: Joseph Bonner
runews@rockvax.rockefeller.edu
212-327-7900
Rockefeller University
3-Apr-1998


Page: 1 2 3

Related biology news :

1. Rockefeller University scientists take on controversial vibration theory of smell
2. By the year 2050, human population could add 2.6 billion people, reports Rockefeller scientist
3. White House awards National Medal of Science to Rockefeller Universitys James Darnell
4. Lasker Award honors Rockefeller University biochemist for pioneering studies of gene activation
5. Rockefeller scientists identify natural proteins that push stem cells to produce hair, not skin
6. Rockefeller, Weill Cornell researchers find link between estrogen, brain structure changes
7. Rockefeller researchers provide the first functional evidence for mammalian pheromone receptors
8. Another transmembrane protein structure solved by Rockefeller scientists
9. Rockefeller researchers identify defense system in plants
10. Rockefeller University Centennial Symposium to explore biology of drug abuse and addiction
11. Rockefeller University researchers discover immune-cell mechanism that boosts therapeutic antibody potency

Post Your Comments:
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
(Date:12/17/2014)... 17, 2014 Audacity, a leading California-based ... member of the Huntsworth Health Group, is proud to ... team. In her role, Gonzales will serve as Senior ... incredibly honored to welcome a talent of Jamie’s caliber ... Gaëtan Fraikin. “She is a proven healthcare innovation leader ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014   Synageva ... biopharmaceutical company developing therapeutic products for rare disorders, announced ... Conference being held in San Francisco, CA. ... President and Chief Executive Officer, will present on Monday, ... EST).  The presentation will be webcast live and may ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: